Announcements

MDPI is delighted to announce the establishment of the Michele Parrinello Award. Named in honor of Professor Michele Parrinello, the award celebrates his exceptional contributions and his profound impact on the field of computational physical science research.

The award will be presented biennially to distinguished scientists who have made outstanding achievements and contributions in the field of computational physical science—spanning physics, chemistry, and materials science.

About Professor Michele Parrinello

"Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking what is going to happen to me and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”

——Professor Michele Parrinello

Born in Messina in 1945, he received his degree from the University of Bologna and is currently affiliated with the Italian Institute of Technology. Professor Parrinello is known for his many technical innovations in the field of atomistic simulations and for a wealth of interdisciplinary applications ranging from materials science to chemistry and biology. Together with Roberto Car, he introduced ab initio molecular dynamics, also known as the Car–Parrinello method, marking the beginning of a new era both in the area of electronic structure calculations and in molecular dynamics simulations. He is also known for the Parrinello–Rahman method, which allows crystalline phase transitions to be studied by molecular dynamics. More recently, he has introduced metadynamics for the study of rare events and the calculation of free energies.

For his work, he has been awarded many prizes and honorary degrees. He is a member of numerous academies and learned societies, including the German Berlin-Brandenburgische Akademie der Wissenschaften, the British Royal Society, and the Italian Accademia Nazionale dei Lincei, which is the major academy in his home country of Italy.

Award Committee

The award committee will be chaired by Professor Xin-Gao Gong, a computational condensed matter physicist, academician of the Chinese Academy of Sciences, and professor at the Department of Physics, Fudan University. Professor Xin-Gao Gong will lead a panel of several senior experts in the field to oversee the evaluation and selection process. The Institute for Computational Physical Sciences at Fudan University (Shanghai, China), led by Professor Xin-Gao Gong, will serve as the supporting institute for the award.

"We hope the Michele Parrinello Award will recognize scientists who have made significant contributions to the field of computational condensed matter physics and at the same time set a benchmark for the younger generation, providing clear direction for their pursuit—this is precisely the original intention behind establishing the award."

——Professor Xin-Gao Gong

The first edition of the award was officially launched on 1 November 2025. Nominations will be accepted before the end of March 2026. For further details, please visit mparrinelloaward.org.

About the MDPI Sustainability Foundation and MDPI Awards

The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which is dedicated to advancing sustainable development through scientific progress and global collaboration. The foundation also oversees the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award. The establishment of the Michele Parrinello Award will further enrich the existing award portfolio, providing continued and diversified financial support to outstanding professionals across various fields. 

In addition to these foundation-level awards, MDPI journals also recognize outstanding contributions through a range of honors, including Best Paper Awards, Outstanding Reviewer Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, Editor of Distinction Awards, and others. These initiatives aim to recognize excellence across disciplines and career stages, contributing to the long-term vitality and sustainability of scientific research.

Find more information on awards here.

The articles below have been selected as 2025 Issue Cover Articles by the Editorial Office of Current Oncology (ISSN: 1718-7729). These articles came from multiple fields within the scope of Clinical Oncology, and we hope they can provide insights and references for scholars in related fields.

	1. “Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery” by Luke R. Jackson, Anna Erickson, Kevin Camphausen and Andra V. Krauze Curr. Oncol. 2025, 32(1), 16; https://doi.org/10.3390/curroncol32010016 Available online: https://www.mdpi.com/1718-7729/32/1/16
	2. “Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma” by Grace Wu, Oliver J. Standring, Daniel A. King, Sepideh Gholami, Craig E. Devoe, Cornelius A. Thiels, Travis E. Grotz, Matthew J. Weiss, Richard L. Whelan et al. Curr. Oncol. 2025, 32(2), 103; https://doi.org/10.3390/curroncol32020103 Available online: https://www.mdpi.com/1718-7729/32/2/103
	3. “HPV and Cervical Cancer—Biology, Prevention, and Treatment Updates” by Emilia Włoszek, Kamila Krupa, Eliza Skrok, Michał Piotr Budzik, Andrzej Deptała and Anna Badowska-Kozakiewicz Curr. Oncol. 2025, 32(3), 122; https://doi.org/10.3390/curroncol32030122 Available online: https://www.mdpi.com/1718-7729/32/3/122
	4. “Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment” by Saqib Raza Khan and Daniel Breadner Curr. Oncol. 2025, 32(4), 206; https://doi.org/10.3390/curroncol32040206 Available online: https://www.mdpi.com/1718-7729/32/4/206
	5. “Precision Medicine for Pediatric Glioma and NF1-Associated Tumors: The Role of Small Molecule Inhibitors” by Samuele Renzi, Julie Bennett, Nirav Thacker and Chantel Cacciotti Curr. Oncol. 2025, 32(5), 280; https://doi.org/10.3390/curroncol32050280 Available online: https://www.mdpi.com/1718-7729/32/5/280
	6. “Myelofibrosis: Treatment Options After Ruxolitinib Failure” by Ruth Stuckey, Adrián Segura Díaz and María Teresa Gómez-Casares Curr. Oncol. 2025, 32(6), 339; https://doi.org/10.3390/curroncol32060339 Available online: https://www.mdpi.com/1718-7729/32/6/339
	7. “Associations Between Symptom Complexity and Acute Care Utilization Among Adult Advanced Cancer Patients Followed by a Palliative Care Service” by Philip Pranajaya, Vincent Ho, Mengzhu Jiang, Vance Tran and Aynharan Sinnarajah Curr. Oncol. 2025, 32(7), 388; https://doi.org/10.3390/curroncol32070388 Available online: https://www.mdpi.com/1718-7729/32/7/388
	8. “Barriers and Enablers to Engaging with Long-Term Follow-Up Care Among Canadian Survivors of Pediatric Cancer: A COM-B Analysis” by Holly Wright, Sharon H. J. Hou, Brianna Henry, Rachelle Drummond, Kyle Mendonça, Caitlin Forbes, Iqra Rahamatullah, Jenny Duong, Craig Erker, Michael S. Taccone et al. Curr. Oncol. 2025, 32(8), 427; https://doi.org/10.3390/curroncol32080427 Available online: https://www.mdpi.com/1718-7729/32/8/427
	9. “Dual PET Imaging with [68Ga]Ga-DOTA-TOC and [18F]FDG to Localize Neuroendocrine Tumors of Unknown Origin” by Ali Zaidi, Pavithraa Ravi, Ingrid Bloise, Sara Harsini, Heather C. Stuart, Hagen F. Kennecke, Ian Alberts, François Bénard, Don Wilson, Patrick Martineau and Jonathan M. Loree Curr. Oncol. 2025, 32(9), 497; https://doi.org/10.3390/curroncol32090497 Available online: https://www.mdpi.com/1718-7729/32/9/497
	10. “A Goal Without a Plan Is Just a Wish—Creating a Personalized Aftercare Plan for Breast Cancer Patients Supported by the Breast Cancer Aftercare Decision Aid” by A. Dekker-Klaassen, C. H. C. Drossaert, R. Thé, A. M. Zeillemaker, M. van Hezewijk, I. M. De Keulenaar-Suiker, B. J. Knottnerus, A. Honkoop, M. L. van der Lee, J. C. Korevaar, S. Siesling and on behalf of the NABOR Project Group Curr. Oncol. 2025, 32(10), 552; https://doi.org/10.3390/curroncol32100552 Available online: https://www.mdpi.com/1718-7729/32/10/552
	11. “HPV Testing, Self-Collection, and Vaccination: A Comprehensive Approach to Cervical Cancer Prevention” by Shannon Salvador † on behalf of An Advisory Committee of Federal and Provincial Experts in Support of Reducing Cervical Cancer Incidence and Advancing Equitable Healthcare for Al Curr. Oncol. 2025, 32(11), 594; https://doi.org/10.3390/curroncol32110594 Available online: https://www.mdpi.com/1718-7729/32/11/594
	12. “Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?” by Wensi Tao, Amanda Sabel and R. Daniel Bonfil Curr. Oncol. 2025, 32(12), 692; https://doi.org/10.3390/curroncol32120692 Available online: https://www.mdpi.com/1718-7729/32/12/692

We are pleased to present a selection of title stories published in Current Oncology (ISSN: 1718-7729) during 2025. These articles highlight groundbreaking research and advancements in clinical oncology, and we hope they can provide insights and references for scholars in related fields.

1. “Advancing Research Alongside Patient Partners: Next-Generation Best Practices for Effective Collaboration in Health Research”
by Ally C. Farrell, Jessica A. Lawson, Ovarian Cancer Canada’s Patient Partners in Research Team, Alison Ross and Alicia A. Tone
Curr. Oncol. 2024, 31(11), 6956-6978; https://doi.org/10.3390/curroncol31110513
Available online: https://www.mdpi.com/1718-7729/31/11/513

2. “The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers”
by Ryan Michael Antar, Christopher Fawaz, Diego Gonzalez, Vincent Eric Xu, Arthur Pierre Drouaud, Jason Krastein, Faozia Pio, Andeulazia Murdock, Kirolos Youssef, Stanislav Sobol et al.
Curr. Oncol. 2024, 31(11), 6909-6937; https://doi.org/10.3390/curroncol31110511
Available online: https://www.mdpi.com/1718-7729/31/11/511

3. “Malignant Pleural Effusion: Diagnosis and Treatment—Up-to-Date Perspective”
by Riccardo Orlandi, Andrea Cara, Enrico Mario Cassina, Sara Degiovanni, Lidia Libretti, Emanuele Pirondini, Federico Raveglia, Antonio Tuoro, Sara Vaquer, Stefania Rizzo et al.
Curr. Oncol. 2024, 31(11), 6867-6878; https://doi.org/10.3390/curroncol31110507
Available online: https://www.mdpi.com/1718-7729/31/11/507

4. “Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting”
by Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, Laura Bonanno, Emilio Bria, Diego Luigi Cortinovis, Stefano Margaritora, Francesca Mazzoni, Edoardo Mercadante, Alessandro Morabito et al.
Curr. Oncol. 2025, 32(2), 110; https://doi.org/10.3390/curroncol32020110
Available online: https://www.mdpi.com/1718-7729/32/2/110

5. “When “One Size Fits All” Fits None: A Commentary on the Impacts of the “Draft Canadian Breast Cancer Screening Guidelines” on Racialized Populations in Canada”
by Beverley Osei, Gayathri Naganathan, Juliet M. Daniel, Supriya Kulkarni, Aisha Lofters, Yinka Oladele, Leila Springer and Mojola Omole
Curr. Oncol. 2025, 32(3), 123; https://doi.org/10.3390/curroncol32030123
Available online: https://www.mdpi.com/1718-7729/32/3/123

6. “Feasibility and Acceptability of Social Prescribing for Cancer Survivors”
by Deirdre Connolly, Chloe O’Hara, Catherine O’Brien and Adrienne Dempsey
Curr. Oncol. 2025, 32(3), 129; https://doi.org/10.3390/curroncol32030129
Available online: https://www.mdpi.com/1718-7729/32/3/129

7. “Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma”
by Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose et al.
Curr. Oncol. 2025, 32(4), 238; https://doi.org/10.3390/curroncol32040238
Available online: https://www.mdpi.com/1718-7729/32/4/238

8. “Implementation of Organ Preservation for Locally Advanced Rectal Cancer in Canada: A National Survey of Clinical Practice”
by Megan Delisle, Victoria Ivankovic, Doris Goubran, Eliane Yvonne Paglicauan, Mariam Alsobaei, Nicole Alcasid, Mary Farnand and Kristopher Dennis
Curr. Oncol. 2025, 32(6), 341; https://doi.org/10.3390/curroncol32060341
Available online: https://www.mdpi.com/1718-7729/32/6/341

9. “Parents’ Experiences and Clinicians’ Perceptions of Managing Cancer Pain in Young Children at Home”
by Lindsay A. Jibb, Elham Hashemi, Surabhi Sivaratnam, Aimee K. Hildenbrand, Paul C. Nathan, Julie Chartrand, Nicole M. Alberts, Tatenda Masama, Hannah G. Pease, Lessley B. Torres et al.
Curr. Oncol. 2025, 32(10), 538; https://doi.org/10.3390/curroncol32100538
Available online: https://www.mdpi.com/1718-7729/32/10/538

10. “Cervical Cancer Screening Cascade: A Framework for Monitoring Uptake and Retention Along the Screening and Treatment Pathway”
by Sara Izadi-Najafabadi, Laurie W. Smith, Anna Gottschlich, Amy Booth, Stuart Peacock and Gina S. Ogilvie
Curr. Oncol. 2025, 32(7), 407; https://doi.org/10.3390/curroncol32070407
Available online: https://www.mdpi.com/1718-7729/32/7/407

11. “Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy”
by António Paiva-Correia, Joana Apolónio, Alfons Nadal, José Ricardo Brandão, Nádia Silva, Bianca Machado, Ivan Archilla, Pedro Castelo-Branco and Henrik Hellquist
Curr. Oncol. 2025, 32(6), 312; https://doi.org/10.3390/curroncol32060312
Available online: https://www.mdpi.com/1718-7729/32/6/312

12. “Dosimetric Comparison of VMAT Alone and VMAT with HDR Brachytherapy Boost Using Clinical and Biological Dose Models in Localized Prostate Cancer”
by Manuel Guhlich, Olga Knaus, Arne Strauss, Laura Anna Fischer, Jann Fischer, Stephanie Bendrich, Sandra Donath, Leif Hendrik Dröge, Martin Leu, Stefan Rieken et al.
Curr. Oncol. 2025, 32(6), 360; https://doi.org/10.3390/curroncol32060360
Available online: https://www.mdpi.com/1718-7729/32/6/360

13. “Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy”
by Kathrin Halfter, Michael Staehler, Dieter Hölzel, Alexander Crispin and Anne Schlesinger-Raab
Curr. Oncol. 2025, 32(9), 515; https://doi.org/10.3390/curroncol32090515
Available online: https://www.mdpi.com/1718-7729/32/9/515

In January, the WHO-recognized Cervical Cancer Awareness Month features global activities to raise awareness and support for Cervical Cancer research. We would like to take this opportunity to extend our appreciation to all of the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of Cervical Cancer that have been published in MDPI’s Journal Cluster of Oncology: Cancers, Current Oncology, Onco and Targets. We hope this announcement will provide useful information for all individuals interested in this field.

“Long-Term Outcomes of Co-Testing with 3-Type HPV mRNA (16/18/45) and Cytology in Women Under 40: A Real-World Cohort from Northern Norway (8–10 Years of Follow-Up)”
by Marie Bostrøm, Gunnar Skov Simonsen and Sveinung Wergeland Sørbye
Targets 2025, 3(4), 36; https://doi.org/10.3390/targets3040036

“The Role of Tissue Factor-Positive Microparticles in Gynecological Cancer-Associated Disseminated Intravascular Coagulation: Molecular Mechanisms and Clinical Implications”
by Muqaddas Qureshi, Muhammad Tanveer Alam and Ahsanullah Unar
Onco 2025, 5(3), 33; https://doi.org/10.3390/onco5030033

“The Neutrophil-to-Lymphocyte Ratio (NLR) as a Potential Predictor in Conization Outcomes for Cervical Cancer”
by Balázs Vida, Emese Keszthelyi, Zsófia Tóth, Lotti Lőczi, Barbara Sebők, Petra Merkely, Balázs Lintner, Ferenc Bánhidy, Attila Keszthelyi, Szabolcs Várbíró, Richárd Tóth and Márton Keszthelyi
Cancers 2025, 17(11), 1856; https://doi.org/10.3390/cancers17111856

“A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy”
by Iozsef Gazsi and Loredana G. Marcu
Curr. Oncol. 2025, 32(3), 170; https://doi.org/10.3390/curroncol32030170

“Neutrophil/Lymphocyte Ratio (NLR) as a Predictive Marker for p16 Positivity and Cervical Cancer Progression: Insights from the SCOPE Study”
by Zsófia Tóth, Lotti Lőczi, Barbara Sebők, Petra Merkely, Emese Keszthelyi, Balázs Lintner, Nándor Ács, Attila Keszthelyi, Szabolcs Várbíró, Richárd Tóth et al.
Cancers 2025, 17(6), 921; https://doi.org/10.3390/cancers17060921

“Molecular Insights into HR-HPV and HCMV Co-Presence in Cervical Cancer Development”
by Rancés Blanco and Juan P. Muñoz
Cancers 2025, 17(4), 582; https://doi.org/10.3390/cancers17040582

“Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)”
by Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Alfredo Ercoli, Francesco Fanfani et al.
Cancers 2024, 16(14), 2541; https://doi.org/10.3390/cancers16142541

“Impact of PET/CT Imaging with FDG in Locally Advanced Cervical Carcinoma—A Literature Review”
by Ottó Molnar, Oreste Mihai Straciuc, Simona Mihuțiu and Liviu Lazăr
Curr. Oncol. 2024, 31(5), 2508-2526; https://doi.org/10.3390/curroncol31050188

“The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)”
by Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti and David Cibula
Cancers 2024, 16(4), 775; https://doi.org/10.3390/cancers16040775 

“Fertility Preservation in Cervical Cancer—Treatment Strategies and Indications”
by Lina Salman and Allan Covens
Curr. Oncol. 2024, 31(1), 296-306; https://doi.org/10.3390/curroncol31010019

“Cervical Cancer Screening: Current Practices and Future Perspectives” Guest Editor: Dr. Kimon Chatzistamatiou Submission deadline: 20 March 2026	“Clinical Management of Cervical Cancer” Guest Editor: Dr. Vanessa Samouëlian Submission deadline: 31 March 2026
“The Role of Minimally Invasive and Minimally Radical Surgery in Cervical and Endometrial Cancer” Guest Editors: Dr. Raj Naik, Dr. Marie Plante, Dr. Christophe Pomel, Prof. Dr. Roberto Tozzi and Dr. Gwénaël Ferron Submission deadline: 1 September 2026	“Medical Image-Based Cervical Cancer Prevention, Diagnosis, and Treatment” Guest Editors: Dr. Emma R. Allanson and Dr. Ming Yin Lin Submission deadline: 30 September 2026

“Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer” Edited by Ranjit Manchanda https://doi.org/10.3390/books978-3-0365-2983-7 This is a Reprint of the Special Issue Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer that was published in Cancers.

We have expanded our open access portfolio with eight new journals publishing their inaugural issues in December 2025, as well as three journal transfers. These additions span physical sciences, social sciences, arts and humanities, environmental and Earth sciences, medicine and pharmacology, and public health and healthcare. We extend our sincere thanks to the Editors-in-Chief, Associate Editors, and Editorial Board Members who are shaping these journals’ direction. All journals uphold strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).

The goal of the Editor’s Choice Articles project is to promote high-quality articles published in Current Oncology (ISSN: 1718-7729). We are pleased to share the following articles carefully handpicked by the scientific editors of the journal, which we believe will be of interest to you. The full list of Editor's Choice Articles can be viewed at the following link: https://www.mdpi.com/journal/curroncol/editors_choice.

1. “Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan”
by Tomoki Taniguchi, Koji Iinuma, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Masayuki Tomioka, Makoto Kawase, Kota Kawase, Keita Nakane, Yuki Tobisawa et al.
Curr. Oncol. 2024, 31(12), 7914-7923; https://doi.org/10.3390/curroncol31120583
Available online: https://www.mdpi.com/1718-7729/31/12/583

2. “Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response”
by Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yoshihiko Tachi, Takeshi Ukai, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka et al.
Curr. Oncol. 2024, 31(10), 6218-6231; https://doi.org/10.3390/curroncol31100463
Available online: https://www.mdpi.com/1718-7729/31/10/463

3. “Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes”
by Marcin Jezierzański, Natalia Nafalska, Małgorzata Stopyra, Tomasz Furgoł, Michał Miciak, Jacek Kabut and Iwona Gisterek-Grocholska
Curr. Oncol. 2024, 31(7), 3994-4002; https://doi.org/10.3390/curroncol31070296
Available online: https://www.mdpi.com/1718-7729/31/7/296

4. “Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery”
by Hala Muaddi, LaDonna Kearse and Susanne Warner
Curr. Oncol. 2024, 31(4), 2260-2273; https://doi.org/10.3390/curroncol31040167
Available online: https://www.mdpi.com/1718-7729/31/4/167

5. “BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer”
by Sarah Lidagoster, Reuben Ben-David, Benjamin De Leon and John P. Sfakianos
Curr. Oncol. 2024, 31(2), 1063-1078; https://doi.org/10.3390/curroncol31020079
Available online: https://www.mdpi.com/1718-7729/31/2/79

6. “Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma”
by Gaetano Pezzicoli, Federica Ciciriello, Vittoria Musci, Francesco Salonne, Anna Ragno and Mimma Rizzo
Curr. Oncol. 2023, 30(10), 9276-9290; https://doi.org/10.3390/curroncol30100670
Available online: https://www.mdpi.com/1718-7729/30/10/670

7. “Education, Employment, and Financial Outcomes in Adolescent and Young Adult Cancer Survivors—A Systematic Review”
by Aurelia Altherr, Céline Bolliger, Michaela Kaufmann, Daniela Dyntar, Katrin Scheinemann, Gisela Michel, Luzius Mader and Katharina Roser
Curr. Oncol. 2023, 30(10), 8720-8762; https://doi.org/10.3390/curroncol30100631
Available online: https://www.mdpi.com/1718-7729/30/10/631

8. “An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma”
by Thomas Joyce, Sarisha Jagasia, Erdal Tasci, Kevin Camphausen and Andra Valentina Krauze
Curr. Oncol. 2023, 30(9), 8278-8293; https://doi.org/10.3390/curroncol30090601
Available online: https://www.mdpi.com/1718-7729/30/9/601

9. “Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review”
by Caitlin Lazurko, Revital Linder, Kate Pulman, Genevieve Lennox, Tomer Feigenberg, Rouhi Fazelzad, Taymaa May and Tiffany Zigras
Curr. Oncol. 2023, 30(9), 8159-8171; https://doi.org/10.3390/curroncol30090592
Available online: https://www.mdpi.com/1718-7729/30/9/592

10. “Prospective Clinical Trials to Advance the Study of Immune Checkpoint Inhibitor Toxicity”
by Christopher Cluxton and Jarushka Naidoo
Curr. Oncol. 2023, 30(7), 6862-6871; https://doi.org/10.3390/curroncol30070502
Available online: https://www.mdpi.com/1718-7729/30/7/502

MDPI will attend The World Congress of Nephrology 2026 (WCN’26), which will take place from 28 to 31 March 2026, in Yokohama, Japan.

The International Society of Nephrology (ISN) invites you to participate in its flagship congress, co-hosted by the Japanese Society of Nephrology (JSN) and the Asian Pacific Society of Nephrology (APSN). Marking a highly anticipated return to Japan after 36 years, WCN’26 will gather over 4,000 kidney professionals from around the globe to advance kidney health worldwide. This prestigious congress offers a unique platform to exchange knowledge, discover the latest scientific and clinical advances, and engage in meaningful discussions with leading experts in nephrology.

MDPI is excited to participate in this prominent international event. We warmly welcome you to visit our booth (#2), where you will have the opportunity to meet our representatives face-to-face and learn more about our open access publishing services.

The following MDPI journals will be represented:

• JCM;
• Kidney and Dialysis;
• Biomedicines;
• Cancers;
• Current Oncology;
• Clinics and Practice;
• Diseases;
• Immuno;
• JMP;
• JPM;
• Toxins;
• Transplantology.

If you plan to attend this event, we encourage you to visit our booth and speak to our representatives. We are eager to meet you in person and assist you with any queries that you may have. For more information about the conference, please visit the official website: https://www.theisn.org/wcn/.

We are pleased to announce that Dr. Zhiyuan Xu has been appointed Section Editor-in-Chief of the Section “Neuro-Oncology” in Current Oncology (ISSN: 1718-7729).

Dr. Zhiyuan Xu, MD, was born in China and completed his residency training in neurosurgery there before pursuing research at the Lady Davis Institute at McGill University in Montreal, Canada, where he focused on DNA repair mechanisms and anticancer drug resistance in glioblastoma. He subsequently completed a neurosurgical oncology fellowship at the Cleveland Clinic’s Neurological Institute from 2007 to 2010. In 2010, he joined the Department of Neurosurgery at the University of Virginia Health System. His clinical subspecialty is stereotactic radiosurgery, and he completed dedicated fellowship training in this area under Jason Sheehan, MD, PhD.

Dr. Xu is a principal investigator and collaborator on multiple research projects involving focused ultrasound. He has authored more than 140 peer-reviewed publications in stereotactic radiosurgery and 26 papers in basic science disciplines, including DNA repair and focused ultrasound–related research. He has also contributed numerous book chapters on DNA repair and stereotactic radiosurgery. In addition, he serves as an ad hoc reviewer for several leading journals, including Lancet Oncology, the International Journal of Radiation Oncology, Biology, and Physics, Neurosurgical Focus, Neurosurgical Review, the Journal of Neurosurgery, Cancers, Current Oncology, the Journal of Neurorestoratology, and World Neurosurgery, among others. He has also served as an abstract reviewer for the Society for Neuro-Oncology (SNO) annual conference since 2019.

The following is a short Q&A with Dr. Zhiyuan Xu, who shared his vision for the journal with us, as well as his views of the research area and open access publishing:

1. What appealed to you about the journal that made you want to take the role of Section Editor-in-Chief?
What initially attracted me to Current Oncology was the journal’s focus on clinically meaningful, evidence-based research that directly impacts patient care. When I began as an ad hoc reviewer in 2022, I appreciated the journal’s commitment to rigor, transparency, and constructive peer review. That experience made it clear that Current Oncology valued both scientific depth and practical relevance—something that resonates strongly with my own work as a physician–scientist in neurosurgery.
As my role grew into Academic Editor, I became even more engaged with the journal’s mission. I particularly valued the opportunity to help authors strengthen manuscripts spanning clinical practice, radiosurgical innovation, and translational neuro-oncology research. Given my background in Gamma Knife radiosurgery, focused ultrasound, and DNA damage and repair, I was excited by how the journal bridges fundamental mechanisms with real-world therapeutic applications.
Stepping into the role of Section Editor-in-Chief appealed to me because it offers the chance to shape the scientific direction of a field undergoing rapid evolution. I hope to continue fostering a Section that highlights rigorous methodology, emerging therapeutic technologies, and high-impact translational advances. It is a privilege to help guide work that aligns with my clinical and research passions and contributes meaningfully to the neuro-oncology community.

2. What is your vision for the journal and Section?
My vision for the Section is to establish it as a trusted, forward-looking platform where clinically meaningful research and emerging technological advancements converge. Current Oncology is uniquely positioned to bridge rigorous scientific discovery with real-world patient care, and I hope for our Section to help lead that integration.
By promoting robust methodology, clear reporting, and thoughtful peer review, we can ensure that the work we publish not only advances science but also informs clinical decision-making. This includes encouraging studies that integrate molecular profiling, radiogenomics, and advanced imaging.
With rapid developments in liquid biopsy, stereotactic radiosurgery, focused ultrasound, and DNA damage and repair, our Section should highlight research that pushes boundaries—whether through precision therapies, novel delivery systems, or translational insights that connect bench to bedside.
Open access allows us to reach clinicians, scientists, and trainees worldwide. I aim to cultivate submissions that reflect diverse perspectives, multidisciplinary approaches, and even statistically nonsignificant but clinically meaningful findings—ensuring that all insights that matter to patient care have a place in the literature.
The 2025 WFNOS/SNO Annual Meeting—celebrating SNO’s 30th anniversary and drawing participants from more than 40 countries—underscores the strength of our international neuro-oncology community. Collaboration among global societies such as WFNOS, EANO, and ASNO exemplifies the cross-disciplinary exchange that drives innovation in areas including AI-enabled research, liquid biopsy, and clinical trials.
Ultimately, my goal is to build a Section that is authoritative, innovative, and inclusive—one that elevates impactful science and advances the field while remaining firmly grounded in clinical relevance.

3. What does the future of this field of research look like?
The future of neuro-oncology is defined by increasing precision—biologically, radiographically, and therapeutically. We are moving away from broad treatment paradigms toward approaches that integrate molecular signatures, radiogenomics, and real-time image guidance to personalize therapy at an unprecedented level.
In neurosurgical oncology, the next decade will bring major advances in minimally invasive and noninvasive technologies. Focused ultrasound and stereotactic radiosurgery will expand beyond local tumor control into applications such as blood–brain barrier opening, targeted drug delivery, and immunomodulation. These technologies will increasingly converge with our growing understanding of DNA damage and repair pathways, enabling us to exploit tumor-specific vulnerabilities with exceptional precision.
We will also see a shift toward multimodal treatment strategies—integrating radiation, systemic agents, immunotherapies, and device-based technologies into unified, biologically informed care plans. Artificial intelligence will further accelerate this evolution through enhanced imaging interpretation, prediction of treatment response, and optimization of radiosurgical planning.
Overall, the field is moving toward therapies that are more targeted, less invasive, and deeply informed by molecular biology. This convergence of technology and biological insight will redefine how we manage complex tumors and improve both survival and quality of life for patients.

4. What do you think of the development of open access in the publishing field?
The growth of open access has been one of the most transformative developments in scientific publishing. At its core, open access democratizes knowledge—making high-quality research available to clinicians, scientists, and patients regardless of institutional or geographic barriers. In neuro-oncology, where timely access to emerging findings can influence patient care, this accessibility has real impact.
Open access also promotes transparency and accelerates scientific progress. When data and methods are freely available, findings can be validated, improved upon, and translated more rapidly. This is particularly important in fast-moving areas such as stereotactic radiosurgery, focused ultrasound, liquid biopsy, and molecular oncology, where cross-disciplinary collaboration drives innovation.
At the same time, the field is still evolving. Sustainable publication models and consistent editorial standards remain important to ensure that open access maintains both rigor and integrity. Journals that combine accessibility with strong peer review—such as Current Oncology—are helping set that standard.
Overall, open access strengthens the global research community. It broadens participation, increases visibility for authors, and ensures that new discoveries reach those who can apply them to advance science and improve patient outcomes.

We wish Dr. Zhiyuan Xu every success in his new position, and we look forward to his contributions to the journal.

International Universal Health Coverage Day, observed annually on 12 December, is a global response to the rallying cry: “Unaffordable health costs? We’re sick of it!” This day confronts the stark reality that millions are excluded from essential care due to financial barriers and mobilizes the world to transform health systems from privileges into universal rights.

Aligned with this year’s theme and Sustainable Development Goal 3: Good Health and Well-Being, MDPI underscores that research is not an academic exercise—it is a vital tool for diagnosing system failures and prescribing equitable solutions. From health economics studies that expose catastrophic spending, to innovations in low-cost diagnostics and community-based insurance models, researchers are providing the evidence and innovations to turn public frustration into actionable policy.

Join us in observing International Universal Health Coverage Day and supporting efforts to turn the promise of health for all into a tangible reality.

“Trends, Challenges, and Socioeconomic Impacts of HIV in Bangladesh: A Data-Driven Analysis (2000–2024)”
by Awnon Bhowmik, Mahmudul Hasan, Mrinal Saha and Goutam Saha
Sexes 2025, 6(3), 34; https://doi.org/10.3390/sexes6030034

“Development and Metrological Characterization of Low-Cost Wearable Pulse Oximeter”
by Andrea Cataldo, Enrico Cataldo, Antonio Masciullo and Raissa Schiavoni
Bioengineering 2025, 12(3), 314; https://doi.org/10.3390/bioengineering12030314

“Consequences of Hospital Closures for the Health Insurance Industry in the United States”
by Rainer W. G. Gruessner
Hospitals 2025, 2(1), 2; https://doi.org/10.3390/hospitals2010002

“Enhancing Therapy Adherence: Impact on Clinical Outcomes, Healthcare Costs, and Patient Quality of Life”
by Urszula Religioni, Rocío Barrios-Rodríguez, Pilar Requena, Mariola Borowska and Janusz Ostrowski
Medicina 2025, 61(1), 153; https://doi.org/10.3390/medicina61010153

“Human Rights and Inclusion of Vulnerable Groups in Health and Well-Being Policy Documents Relevant to Children and Young People in Ireland”
by Megan Lambert and Joanne McVeigh
Int. J. Environ. Res. Public Health 2024, 21(9), 1252; https://doi.org/10.3390/ijerph21091252

“Multidimensional Impact of Dupilumab on Chronic Rhinosinusitis with Nasal Polyps: A Complete Health Technology Assessment of Clinical, Economic, and Non-Clinical Domains”
by Ignazio La Mantia, Giancarlo Ottaviano, Martina Ragusa, Matteo Trimarchi, Emanuela Foglia, Fabrizio Schettini, Daniele Bellavia and Elena Cantone
J. Pers. Med. 2024, 14(4), 347; https://doi.org/10.3390/jpm14040347

“Factors in Immigrant Children’s Use of Physician and Dentist Visits, Hospital Care, and Prescribed Medication in the United States”
by Tyrone C. Cheng and Celia C. Lo
Eur. J. Investig. Health Psychol. Educ. 2023, 13(10), 2251-2261; https://doi.org/10.3390/ejihpe13100159

“Cost Analysis of Magnetic Resonance Imaging and Computed Tomography in Cardiology: A Case Study of a University Hospital Complex in the Euro Region”
by Francisco Reyes-Santias, Carlos García-García, Beatriz Aibar-Guzmán, Ana García-Campos, Octavio Cordova-Arevalo, Margarita Mendoza-Pintos, Sergio Cinza-Sanjurjo, Manuel Portela-Romero, Pilar Mazón-Ramos and Jose Ramon Gonzalez-Juanatey
Healthcare 2023, 11(14), 2084; https://doi.org/10.3390/healthcare11142084

“Financial Toxicity and Out-of-Pocket Costs for Patients with Head and Neck Cancer”
by Justin Smith, Justin Yu, Louisa G. Gordon and Madhavi Chilkuri
Curr. Oncol. 2023, 30(5), 4922-4935; https://doi.org/10.3390/curroncol30050371

“Disentangling the Cost of Orphan Drugs Marketed in the United States”
by Hana Althobaiti, Enrique Seoane-Vazquez, Lawrence M. Brown, Marc L. Fleming and Rosa Rodriguez-Monguio
Healthcare 2023, 11(4), 558; https://doi.org/10.3390/healthcare11040558

“3D Printing in LMICs: Functional Design for Upper Limb Prosthetics in Uganda”
by Ali Hussaini, Peter Kyberd, Benedict Mulindwa, Robert Ssekitoleko, William Keeble, Laurence Kenney and David Howard
Prosthesis 2023, 5(1), 130-147; https://doi.org/10.3390/prosthesis5010011

The 1st International Online Conference on Clinical Reports Organizer: MDPI and Reports Volume Editor: Toshio Hattori Highlights Improving Bone Protection Provision for Patients with Fragility Fractures by Aaron Goldberg Leveraging Digital Health for Pandemic Response: Reliable Telemonitoring and Personalized Patient Care by Maria Montserrat Pérez García et al. Click here to read the full list of papers.